New Technologies: The Good, the Bad, and the Ugly

By Eric Hollander, MD

This month’s issue deals with new technology that has the potential not only to advance human health but also to create new and unexpected forms of human suffering.

DNA microarrays have tremendous promise for the development of personalized medicine, allowing physicians to select specific treatments to maximize therapeutic efficacy and to minimize side effects, based on an individual’s unique genetic profile. They allow for the simultaneous testing of thousands of DNA sequences, and the AmpliChip CYP450 test employs this technology for cytochrome P450 (CYP) 2D6 and CYP2C19 genotyping. Isoenzymes coded by these genes metabolize many prescribed drugs. Jose de Leon, MD, and colleagues identified these alleles and phenotypes in 4,532 psychiatric patients. The prevalence of CYP2D6 poor metabolizers was 7.6% (8.2% in Caucasians, 1.8% in the African Americans). The prevalence of CYP2D6 ultrarapid metabolizers was 1.5% (1.5% in Caucasians, 2.0% in African Americans). The prevalence of CYP2C19 poor metabolizers was 2.0% (2.2% in Caucasians, 4.0% in African Americans). De Leon and colleagues propose a numeric system for expression of CYP2D6 and CYP2C19 enzyme activity to aid clinicians in determining treatment strategy for patients receiving therapeutics that are metabolized by the CYP2D6 or CYP2C19 gene products. DNA technology is rapidly becoming more powerful, and its costs are rapidly decreasing. However, the practical impact of such technology has been relatively limited to date. One exception is the gene testing for cytochrome isoenzymes involved in metabolizing drugs, which does have some impact in everyday clinical practice. This article is helpful in determining how common slow and rapid metabolizers of CYP gene products are, and how to use this information in determining treatment options.

Alan D. Feiger, MD, and colleagues compared the efficacy and safety of desvenlafaxine succinate versus placebo in treating major depressive disorder (MDD) in a randomized, double-blind study of adult patients with MDD. In this study, the primary analysis did not show significant differences between desvenlafaxine and placebo; discontinuations due to AEs associated with the desvenlafaxine dose range may have contributed to the lack of statistical separation. Discontinuation rates due to adverse events (AEs) were 12% and 3% for desvenlafaxine and placebo, respectively. On secondary measures, differences in week 8 observed cases and at the final evaluation were significant for the primary measures. The most frequently reported AE associated with desvenlafaxine was nausea (36% vs 9%). Thus, in this single trial, avoiding variations in first pass liver metabolism did not eliminate the side effects of the active metabolite.

Dyke-Davidoff-Masson syndrome, or cerebral hemiatrophy, is a pre- or perinatally acquired entity and is characterized by predominantly neurologic symptoms, such as seizures, facial asymmetry, contralateral hemiplegia, and mental retardation. Benedikt Amann, MD, PhD, and colleagues report the first case of left cerebral hemiatrophy and a late onset of treatment-resistant schizoaffective disorder after a stressful life event. The patient finally responded well to clozapine. The clinical history and results from structural neuroimaging are highlighted to discuss the possible developmental bias for psychotic disorders. Thus, psychotic symptoms may occur within the context of a complex neurologic presentation and having a unique developmental trajectory.

New technologies do have the potential to advance human health as well as to lead to unexpected forms of human suffering. DNA microarrays do have tremendous promise for the development of personalized medicine.

Finally, I would like to express my profound thanks to all of our peer reviewers, listed on the following page. The hard work of these talented and dedicated individuals has allowed the journal to experience a dramatic improvement not only in impact factor (3.409 for Psychiatry and 2.746 for Clinical Neurology), but also in readership interest. CNS

Dr. Hollander is the editor of this journal and director of the Institute of Clinical Neuroscience in New York City.
We would like to thank the following peer reviewers who contributed to CNS Spectrums in 2008:

Lenard Adler, MD
Kevin Antshel, PhD
Donna L. Antonucci, MD, FAAP
Birgit Assmann, PhD
Alireza Atri, MD, PhD
Roger Baird, MD, PhD
Thomas A. Ban, MD, FRCP
David Baron, MSEd, DO
George Bartokis, MD
Randall Bateman, MD
Cesario Bellantuono, MD
Peter Mclaren Black, MD
Carlos Blanco, MD, PhD
Charles L. Bowden, MD
Andrew E. Budson, MD
John Calamari, PhD
Brendan T. Carroll, MD
Franca Centorrino, MD
Jack Chen, PharmD
Joe Clem, MD
Andreas Conca, MD
Bruno Conti, PhD
Josep Dalmau, MD, PhD
Pinhas Dannon, MD
Marilyn Davies, PhD, MSN, RN
Jose de Leon, MD
Bernardo Dell'OssO, MD
Brad Dickerson, MD
Ted Dinan, MD, PhD
Andrew H. Evans, FRACP
Omar Fattal, MD
Giovanni Andrea Fava, MD
Ygor Ferrao, MD, MSc, PhD
Maria Luisa Figueira, MD, PhD
Massimiliano Filosto, MD, PhD
Leonardo F. Fontenelle, MD, PhD
Adriana Foster, MD
Thomas Frazier, PhD
Elbert Geuze, PhD
David L. Ginsberg, MD
Michael Gitlin, MD
John Goethe, MD
Joseph F. Goldberg, MD
Guy Goodwin, DPhil, FMedSci, FRCPsych
Marco A. Grados, MD, MPH
George T. Grossberg, MD
Ruth Gross-Isseroff, DSc
David Gurwitz, PhD
Philip D. Harvey, PhD
Robert A. Hauser, MD
Haggai Hermesh, MD
E. Hogervorst, PhD
Arshad Husain, MD
Charles J. Ippolito, MD
Colleen Jackson-Cook, PhD, FACMG
Jacques Jaeken, MD, PhD
Ari Kalechstein, PhD
David Kemp, MD
Gary J. Kennedy, MD
Scott H. Kollins, PhD
Athanasiou Kourkopoulos, MD
Roger Kurlan, MD
Athanasiou Kyritis, MD
Andrew F. Leuchter, MD
Mark Lew, MD
Paul Links, MD
Chia-Yih Liu, MD
Philip Maiden, MD
Donatella Marazziti, MD
Isaac Marks, MD
J.P. McEvoy, MD
Aaron McMurtray, MD
Herbert Meltzer, MD
Samantha Metzler-Brody, MD
Evans Murray, MD
David J. Muzina, MD
Sharon Naismith, BA, DPsyCh
Humberto Nicolin, MD, PhD
Martin Offenbaecher, MD
Maria A. Oquendo, MD
Stefano Pallanti, MD, PhD
Ilenia Pampaloni, MD
Andreas Papadopoulos, MSc
Joel Paris, MD
James C. Patterson II, MD, PhD
Giulio Perugi, MD
Eric Peselow, MD
Harrison G. Pope, Jr., MD
Anton Porsteinsson, MD
Thomas J. Raedler, MD
J. Russell Ramsay, PhD
Murali Rao, MD, DFAPA, FAPM
James H. Ray, PhD
Nancy S. Redeker, PhD, RN
John Reid, DPhil, BSc, BM, MRCP
Zoltán Rihmer, MD, PhD, DSc
Joe Sam Robinson, Jr, MD
Albina Rodrigues Torres, MD, PhD
Leonardo Rodriguez, MD
Ramon Rodriguez, MD
Timothy A. Roehrs, PhD
Martin J. Sadowski, MD, PhD
Paul Sandor, MD, FRCP
David Sarwer, PhD
Marcelo Schmitz, MD, PhD
Robert Schwarzw, PhD
Lauren C. Seeberger, MD
Mark Stacy, MD
Daniel Stewart, MD
Eric Storch, PhD
Tracy Stroud, DO
Russell H. Swerdlow, MD
Hermano Tavares, MD, PhD
Antonio L. Teixeira, MD, PhD
Per Hove Thomsen, MD
Magda Tsolaki, MD, PhD
Rasit Tukel, MD
Michael Van Ameringen, MD, FRCP
Oriana Vesga, MD
William J. Weiner, MD
Abraham Weizman, MD
David Williams, PhD
Sue Wilson, PhD
Thomas N. Wise, MD